Arvee Laboratories (India) Ltd. (IN:ARVEE)
:ARVEE
Top Page
Arvee Laboratories (India) Ltd.
(ARVEE)
Select Model
Select Model
Rating:54Neutral
Price Target:
₹141.00
▼(-41.81% Downside)
Action:ReiteratedDate:03/25/26
The score is primarily supported by a robust balance sheet, but is held back by weak cash generation and a clear bearish technical setup (below major moving averages with negative MACD). A relatively high P/E and no dividend further limit the attractiveness at the current price.
Positive Factors
Balance sheet strength
Conservative leverage and a strong equity ratio provide enduring financial stability, improving resilience to industry cycles and shocks. Positive ROE indicates shareholder profitability, supporting long-term access to capital and funding for strategic investments without excessive borrowing.
Negative Factors
Weak cash generation
Negative free cash flow and low operating cash flow to net income indicate challenges converting profits into cash. Over months this can constrain capital expenditures, R&D, or working capital needs, forcing external financing or reducing strategic flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Conservative leverage and a strong equity ratio provide enduring financial stability, improving resilience to industry cycles and shocks. Positive ROE indicates shareholder profitability, supporting long-term access to capital and funding for strategic investments without excessive borrowing.
Read all positive factors
Arvee Laboratories (India) Ltd. (ARVEE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹1.48B
Dividend YieldN/A
Average Volume (3M)1.40K
Price to Earnings (P/E)32.2
Beta (1Y)1.04
Revenue Growth-28.88%
EPS Growth-82.29%
CountryIN
Employees65
SectorHealthcare
Sector Strength45
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)1.66
Shares Outstanding11,020,000
10 Day Avg. Volume2,098
30 Day Avg. Volume1,398
Financial Highlights & Ratios
PEG Ratio0.72
Price to Book (P/B)5.18
Price to Sales (P/S)4.20
P/FCF Ratio-93.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Arvee Laboratories (India) Ltd. Business Overview & Revenue Model
Company Description
Arvee Laboratories (India) Ltd. manufactures and sells various specialized chemicals in India. The company provides polymer modifiers, including dimethyl 5-sodiosulfoisophthalate, 5-sulfoisophthalic acid mono sodium salt, 5-sulfoisophthalic acid m...
How the Company Makes Money
null...
Arvee Laboratories (India) Ltd. Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
72
Positive
Cash Flow
50
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 353.65M | 384.87M | 303.42M | 612.76M | 403.27M | 471.44M |
| Gross Profit | 159.88M | 121.63M | 41.49M | 173.09M | 138.08M | 142.99M |
| EBITDA | 31.37M | 42.69M | 35.78M | 86.34M | 61.90M | 61.30M |
| Net Income | 13.74M | 21.47M | 10.52M | 41.19M | 25.74M | 26.77M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 381.58M | 381.99M | 386.85M | 386.85M | 410.46M |
| Cash, Cash Equivalents and Short-Term Investments | 59.75M | 49.06M | 18.65M | 8.92M | 31.08M | 86.39M |
| Total Debt | 0.00 | 10.33M | 10.00M | 10.00M | 31.31M | 88.79M |
| Total Liabilities | -312.61M | 68.97M | 90.85M | 106.23M | 147.43M | 196.08M |
| Stockholders Equity | 312.61M | 312.61M | 291.14M | 280.62M | 239.42M | 214.38M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -17.35M | 10.78M | 14.45M | 16.52M | -5.80M |
| Operating Cash Flow | 0.00 | 1.19M | 36.64M | 29.29M | 40.16M | 17.11M |
| Investing Cash Flow | 0.00 | -17.91M | -21.63M | -12.58M | 592.61K | -6.04M |
| Financing Cash Flow | 0.00 | 333.00K | -1.88M | -24.17M | -60.51M | 45.20M |
Arvee Laboratories (India) Ltd. Technical Analysis
Negative
242.32
Price Trends
157.09
Negative
173.83
Negative
171.54
Negative
Market Momentum
-6.24
Positive
34.54
Neutral
5.71
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ARVEE, the sentiment is Negative. The current price of 242.32 is above the 20-day moving average (MA) of 149.71, above the 50-day MA of 157.09, and above the 200-day MA of 171.54, indicating a bearish trend. The MACD of -6.24 indicates Positive momentum. The RSI at 34.54 is Neutral, neither overbought nor oversold. The STOCH value of 5.71 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ARVEE.
Arvee Laboratories (India) Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | ₹456.15M | 172.45 | ― | ― | 36.76% | 433.63% | |
62 Neutral | ₹909.82M | 111.96 | ― | ― | ― | ― | |
54 Neutral | ₹1.48B | 32.17 | ― | ― | -28.88% | -82.29% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | ₹299.10M | -4.63 | ― | ― | -20.40% | -59.20% | |
39 Underperform | ₹458.51M | -2.21 | ― | ― | -22.42% | 21.83% |
* Healthcare Sector Average
IN:ARVEE
Arvee Laboratories (India) Ltd.
134.20
-12.15
-8.30%
IN:BALAXI
Balaxi Pharmaceuticals Limited
16.48
-50.51
-75.40%
IN:BIOFILCHEM
Biofil Chemicals & Pharmaceuticals Ltd.
28.03
-15.20
-35.16%
IN:LASA
Lasa Supergenerics Ltd.
5.97
-12.13
-67.02%
IN:VIVIMEDLAB
Vivimed Labs Limited
5.53
0.63
12.86%
Arvee Laboratories (India) Ltd. Corporate Events
Arvee Laboratories to Shut Trading Window Ahead of December Quarter Results
Dec 30, 2025
Arvee Laboratories (India) Ltd has announced the closure of its trading window for dealings in its securities from 1 January 2026 until two trading days after the declaration of financial results for the quarter and period ended 31 December 2025. ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.